VTYX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VTYX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Ventyx Biosciences's goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil.
The historical data trend for Ventyx Biosciences's Goodwill can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ventyx Biosciences Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Goodwill | - | - | - | - | - |
Ventyx Biosciences Quarterly Data | |||||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Goodwill | Get a 7-Day Free Trial | - | - | - | - | - |
A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.
Ventyx Biosciences (NAS:VTYX) Goodwill Explanation
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.
It is calculated by dividing goodwill by total assets.
Ventyx Biosciences's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Goodwill-to-Asset (A: Dec. 2023 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 277.693 | |
= |
Ventyx Biosciences's Goodwill-to-Asset Ratio for the quarter that ended in Sep. 2024 is calculated as
Goodwill-to-Asset (Q: Sep. 2024 ) | = | Goodwill | / | Total Assets |
= | 0 | / | 301.1 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Thank you for viewing the detailed overview of Ventyx Biosciences's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.
Raju Mohan | director, officer: Chief Executive Officer | C/O VENTYX BIOSCINECES, INC., 332 ENCINITAS BLVD., SUITE 200, ENCINITAS CA 92024 |
Martin Auster | officer: Chief Financial Officer | C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024 |
John Nuss | officer: Chief Scientific Officer | C/O VENTYX BIOSCIENCES, INC., 332 ENCINITAS BLVD. SUITE 200, ENCINITAS CA 92024 |
Christopher W Krueger | officer: Chief Business Officer | C/O ARDEA BIOSCIENCES INC, 2131 PALOMAR AIRPORT ROAD SUITE 300, CARLSBAD CA 92011 |
Nsv Partners Iii Lp | 10 percent owner | 500 WEST PUTNAM AVE, SUITE 400, GREENWICH CT 06830 |
Somu Subramaniam | director, 10 percent owner | C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062 |
William J. Sandborn | officer: See Remarks | C/O VENTYX BIOSCIENCES, INC., 662 ENCINITAS BLVD. STE 250, ENCINITAS CA 92024 |
Sheila Gujrathi | director | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
William Richard White | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Onaiza Cadoret-manier | director | 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010 |
Allison Hulme | director | C/O SOPHIRIS BIO INC., 1258 PROSPECT ST, LA JOLLA CA 92037 |
Venbio Global Strategic Fund Iii, L.p. | 10 percent owner, other: See Remarks | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Aaron Royston | director, 10 percent owner | 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Iii Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
From GuruFocus
By Marketwired • 06-20-2024
By Marketwired • 11-12-2024
By Marketwired • 06-18-2024
By PRNewswire • 04-30-2024
By Marketwired • 06-08-2024
By Marketwired • 06-15-2024
By Marketwired • 06-04-2024
By Marketwired • 08-08-2024
By Marketwired • 10-15-2024
By GuruFocus News • 11-26-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.